Integration WGCNA with LC-MS Data for Evaluating the Processing Status and Transformation Rules of Ligustri Lucidi Fructus: A Novel Strategy for Evaluating the Processing technology of traditional Chinese medicines

Ligustri Lucidi Fructus (LLF) is a traditional Chinese medicine (TCM) to treat hepatopathy and osteopathy. Wine-processed LLF (WLLF) was much more widely used than raw LLF (RLLF) in clinical practice, however, there is no consensus on processing time. To investigate the processing status of WLLF and transformation rules during processing, a UHPLC-Q-Orbitrap-MS method combined with data-independent acquisition (DIA) mode was firstly established and 227 compounds were identified or tentatively identified. Subsequently, a novel strategy using integration weighted gene co-expression network analysis (WGCNA) with LC-MS data was proposed. A total of 73 differential metabolites were screened out between RLLF and WLLF (wine steaming for 18 h). Meanwhile, the concentration of 11 differential compounds for WLLF was quantified. Finally, correlations between compounds were analyzed by WGCNA and the top five compounds negatively correlated with salidroside were validated, revealing that G13, specnuezhenide, oleuropein, acteoside, and neonuzhenide could be transformed into salidroside and its analogues during processing, respectively. The results indicated that our proposed strategy could be effectively employed to evaluate the processing status of TCMs.